Description
Recommends trades (long and short) based on clinical trials, particularly for smaller pharmaceutical and biotech companies.
If you’ve subscribed to S&A FDA Report (defunct), please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.
Investment Performance
No votes yet... cast yours!
No votes yet.
Please wait...
Your vote
Quality Of Writing/Analysis
No votes yet... cast yours!
No votes yet.
Please wait...
Your vote
Value For Price
No votes yet... cast yours!
No votes yet.
Please wait...
Your vote
Customer Service
No votes yet... cast yours!
No votes yet.
Please wait...
Your vote
I’m an Alliance Member over at Stansberry & Associates, so I’ve seen all their products and used most of them. So far (a few months now), the S&A FDA Report has done the best. I first got in with a great, if somewhat accidental, trade on Dendreon. I read about it one of the free update newsletters, got in just before it spiked, and made 150% on my money in about four days. (I actually did better than Dr. Huang on that one, as I just bought the stock instead of using the hedged option play that he was recommending, but he made money on it too.) That was good enough to convince me to try the service.
Since then most of his recommendations have made money for me. I haven’t taken all of them, but the ones I have taken have either spiked and then stopped back out at a small loss, or else gone for substantial gains. MYRX is the straight stock buy one; I got in at about $4.75 and got out a few weeks later at $6.25 or so. I think his strategy of buying before major FDA decisions on pipeline drugs is a good one. Not all of the drugs get approved, of course, but he seems to have a pretty good feel for which ones will and won’t. An example of making money on one that didn’t is his OSIR play; it involved buying one option at $10 and selling two more at $5 (to help offset the cost) when the stock was at $14. Now, post-FDA decision, the stock is trading around $6.50, which means the position is working precisely as he predicted. Again, he’s not always right, but generally seems to make good calls. And when he’s wrong it’s not for too much money, whereas when he’s right there are generally good double-digit gains.
If you decide to use his service I recommend setting your stop-loss at something less than 25%. I use 20% or 10%, depending.
No customer service rating since I’ve never had to use customer service for this newsletter.
Lost on all his recommendations and could not afford to stay in for very long.
Big mouth no results sorry.